Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02833883
Other study ID # 16-074
Secondary ID c15-160
Status Completed
Phase Phase 1
First received
Last updated
Start date July 2016
Est. completion date January 13, 2023

Study information

Verified date January 2023
Source Memorial Sloan Kettering Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this study to define the good and/or bad effects of the combination of enzalutamide and CC-115 in patients with castration-resistant prostate cancer.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date January 13, 2023
Est. primary completion date January 13, 2023
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Willing and able to provide written informed consent and HIPAA authorization for the release of personal health information. NOTE: HIPAA authorization may be either included in the informed consent or obtained separately. - Males 18 years of age and above with a life expectancy of at least 6 months. - Histological or cytological proof of prostate cancer - Willing to provide a tumor sample via biopsy from a metastatic site of disease to be collected at screening if safe and feasible per treating investigator discretion. Adequate archival tissue can be used if available in lieu of baseline biopsy. - Documented progressive metastatic CRPC based on at least one of the following criteria: - Rise in PSA: a minimum of 3 rising levels, with an interval of at least 1 week between each determination. The last determination must have a value =1 ng/mL, obtained within 4 weeks of starting study drug - Measurable disease: new or progressive soft tissue disease on computerized tomography (CT) or magnetic resonance imaging - Radionuclide bone scan: at least 2 new bone lesions, as defined by the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria33 - Serum testosterone < 50 ng/dL. Patients must continue primary androgen deprivation with an LHRH analogue (agonist or antagonist) if they have not undergone orchiectomy - ECOG performance status of 0-1 - Finasteride, bicalutamide and nilutamide discontinued at least 4 weeks prior to registration. - Physiologic doses of corticosteroids are permitted (i.e., no more than 10mg of prednisone daily). - At least 4 weeks must have elapsed from the use of palliative radiation, Strontium-89, Radium-223, or approved immunotherapy prior to registration. - Less than or equal to 5 half lives or 4 weeks, whichever is shorter, from the use of any investigational therapy prior to registration. - Normal organ function with acceptable initial laboratory values within 14 days of registration. - ANC = 1,500/µl - Hemoglobin = 9g/dL - Platelet count = 100,000/µl - Creatinine = 1.5 x the institutional upper limit of normal (ULN), or 24-hr clearance =50 mL/min - Potassium = 3.5 mmol/L (within institutional normal range, or correctable with supplements) - Bilirubin = 1.5 x ULN (unless documented Gilbert's disease) - SGOT (AST) = 2.5 x ULN - SGPT (ALT) = 2.5 x ULN - Glycated hemoglobin (HbA1c < 6.4% - Able to take oral medication without crushing, dissolving or chewing tablets. - Able to adhere to the study visit schedule and other protocol requirements. Exclusion Criteria: - Prior exposure to enzalutamide, ARN-509, or other investigational AR-directed therapy - Prior exposure to abiraterone acetate, ketoconazole or other specific CYP-17 inhibitors - Prior exposure to agents specifically targeting both mTOR complexes (dual TORC1+TORC2 inhibitors) and/or PI3K/AKT pathways - Prior chemotherapy for castration resistant disease. Chemotherapy given in the castration-sensitive setting is permissible. At least 6 months from registration must have elapsed since chemotherapy was last received. - Symptomatic central nervous system metastases - Known history of acute or chronic pancreatitis - Persistent diarrhea or malabsorption = NCI CTCAE Grade 2, despite medical management - Clinically significant cardiac diseases, including any of the following: - Unstable angina pectoris - Myocardial infarction = 3 months prior to registration - Other clinically significant heart disease such as congestive heart failure requiring treatment or uncontrolled hypertension - Uncontrolled diabetes mellitus - Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol - Major surgery = 2 weeks prior to registration or who have not recovered from side effects of such therapy. Subjects must have recovered from any effects of recent radiotherapy that might confound the safety evaluation of study drug. - Hematopoietic stem cell transplant = 3 months prior to registration. - Adults of reproductive potential not employing two forms of birth control: - Males having partners who are female with child-bearing potential must agree that they and/or their partners will use at least two effective contraceptive methods (including one barrier method) when engaging in reproductive sexual activity throughout the study from the time of informed consent, and will avoid conceiving for 28 days after the last dose of CC-115. - Known human immunodeficiency virus (HIV) infection - Known chronic hepatitis B or C virus (HBV/HCV) infection - Concurrent active second malignancy for which the subject is receiving therapy, other than non-melanomatous skin cancer or superficial transitional cell carcinoma. - History of seizure or any condition that may predispose to seizure including, but not limited to, underlying brain injury, stroke in the past 6 months, primary brain tumors, brain metastases - Active treatment with medications that lower the seizure threshold which cannot be held: - Aminophylline/theophylline; - Atypical antipsychotics (e.g., clozapine, olanzapine, risperidone, ziprasidone); - Bupropion; - Lithium; - Pethidine; - Phenothiazine antipsychotics (e.g., chlorpromazine, mesoridazine, thioridazine); - Tricyclic and tetracyclic antidepressants (e.g., amitriptyline, desipramine, doxepin, imipramine, maprotiline, mirtazapine). - Any other condition which, in the opinion of the Investigator, would preclude participation in this trial

Study Design


Intervention

Drug:
Enzalutamide

CC-115


Locations

Country Name City State
United States John Hopkins Medical Center Baltimore Maryland
United States Duke University Medical Center Durham North Carolina
United States Memorial Sloan Kettering Cancer Center New York New York
United States University of California San Francisco San Francisco California
United States University of Washington School of Medicine Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center Celgene Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary establish the maximum tolerated dose (MTD) Subjects will be treated in cohorts of size three and six and the dosage will be escalated if the clinical toxicity is acceptable. The maximum tolerated dose is defined as the highest dose level with an observed incidence of DLT in no more than one out of six subjects treated at a particular dose level. A DLT will be determined by cycle 1 toxicity, although all-cycle toxicity will be recorded. 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A